Tests individualized everolimus dosing in metastatic breast cancer
Tests everolimus, tailored to each person, in adults with metastatic breast cancer.
Key facts
- Who runs it
- Orszagos Onkologiai Intezet
- Where
- Budapest XII, HungarySee the site
- Trial code
- Registry title
- Individualized everolimus therapy in metastatic breast cancer
- Status
- Not yet recruiting
- Phase
- Phase 2
- People taking part
- 64 people, planned
- Started
- 1 Jan 2025
- Expected to end
- 31 Dec 2027
- Type of study
- Interventional
- Record updated
- 19 March 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with estrogen receptor positive, HER2 negative breast cancer that cannot be removed by surgery or has spread, who have already had hormone-based treatment with a CDK4/6 inhibitor.
- Age
- Over 18 years
- Sex
- All sexes can join. Premenopausal women and men must also use a GNRH analogue.
- Disease stage
- Invasive breast cancer, proven by tissue testing, that is estrogen receptor positive and HER2 receptor negative. It cannot be removed by surgery or has spread. ECOG performance status 0-1.
- Earlier treatment
- At least one earlier line of hormone-based palliative therapy that included a CDK4/6 inhibitor. Earlier palliative chemotherapy is allowed.
- Biomarker or test result
- Estrogen receptor positive and HER2 receptor negative tumour.
Main reasons for not taking part
- Significant heart disease, such as a serious rhythm problem, heart attack or unstable angina within 6 months, long QT syndrome or heart failure
- Another serious acute or chronic illness that the treating doctor judges would make treatment too risky
- Pregnancy, or not agreeing to use a non-hormonal method of contraception
- Known allergy to everolimus, exemestane or their components
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- patient over 18 years of age
- histologically proven estrogen receptor positive and HER2 receptor negative invasive breast tumour
- Irresectable or metastatic disease
- satisfactory overall performance status: ECOG 0-1
- adequate organ function a. Neutrophil count ≥ 1.5 G/l, platelet count ≥ 100 G/l, haemoglobin ≥ 10 g/dl b. GOT/GPT less than 2.5 times the upper limit of the normal range (5 times in case of liver metastasis) c. bilirubin less than 1,5 times the upper limit of the normal range (except Gilbert's disease where less than 3 times) d. creatinine less than 1,5 times the upper limit of the normal range or eGFR higher than 60 ml/min
- at least one previous line of endocrine-based palliative therapy that included a CDK4/6 inhibitor
- previous palliative chemotherapy is allowed
- Postmenopausal female patient, or if premenopausal female or male patient, simultaneous use of GNRH analogue
Who cannot take part
- known allergy or hypersensitivity to everolimus, exemestane or their components
- Known significant cardiac disease: major arrhythmia or significant conduction disturbance (grade 2 or more in severity), infarction or unstable angina within 6 months, collapse of cardiac origin without appropriate therapy, long QT syndrome, heart failure
- any other serious acute or chronic condition (organic or psychiatric disease, laboratory abnormality, severe pulmonary disease) which, in the opinion of the treating physician, would result in an unacceptable increase in the risk of therapy
- Pregnancy or if the patient does not agree to use an appropriate non-hormonal method of contraception
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- What did the tests on your tumour show about hormone receptors and the HER2 protein?
- Have you already had any medicine for your cancer after it spread or became advanced?
- Have you been treated with a CDK4/6 inhibitor (for example palbociclib, ribociclib or abemaciclib)?
Where in Hungary
- Orszagos Onkologiai IntezetBudapest XII, HungaryNot yet recruiting
About the trial
What the trial wants to find out
Change in the quality of life in the two study arms, examined with the FACT-B quality of life test
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Individualized everolimus therapy in metastatic breast cancer
- Plain-language title
- Tests individualized everolimus dosing in metastatic breast cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Fit questions
- Built from 2023-505590-33-06, who can take part
- Record updated
- 19 March 2025